Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | USP14 | P54578 | 1/20 | 0.31 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13568094 | 0.83 | NR1H2 (0.48) | GRM5NPC1RAB9A | |
| SCHEMBL4214604 | 0.83 | HSP90AA1 (0.33) | KDM4EMEN1KMT2ANLRP3GRM5 | |
| SCHEMBL4198490 | 0.81 | MEN1 (0.36) | KDM4EMEN1KMT2ANLRP3GRM5 | |
| SCHEMBL4201295 | 0.77 | KDM4A (0.37) | NOTUMKDM4EMEN1KMT2ANLRP3 | |
| SCHEMBL4201311 | 0.76 | HTR2C (0.36) | ELANE | |
| SCHEMBL4011215 | 0.75 | GRM5 (0.36) | NOTUMMEN1KMT2AGRM5ENPP2 | |
| Hydrochloric Acid SCHEMBL4196496 | 0.75 | HTR2C (0.35) | ELANE | |
| SCHEMBL4203495 | 0.75 | GRM5 (0.38) | NOTUMGRM5ENPP2NPC1RAB9A | |
| SCHEMBL28935833 | 0.74 | GRM5 (0.37) | NOTUMMEN1KMT2AGRM5NPC1 | |
| SCHEMBL4208644 | 0.73 | NOTUM (0.36) | NOTUMKDM4EMEN1KMT2AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | NOTUM 4402/4885KDM4E 2942/4885MEN1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.